CD163 and neoplasm: However, there was no significant difference between the median CD163+ Mɸ counts in the tumours of patients with rs22(GC)+rs30(AG) compared to those with rs22(GC), and of rs22(GC)+rs29(TC) compared to the rs22(CC) genotype (Figure 3b and Table S3).